Arthritis is the most common form of the joint disease affecting estimated millions of people worldwide, including ankylosing spondylitis, gout, juvenile idiopathic arthritis, osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, septic arthritis, thumb arthritis. The most common signs and symptoms of arthritis predominantly involve one or more joints, including joint pain, stiffness, swelling, redness, and functional limitation of affected joints. Despite the underlying etiologies varying in different types of arthritic disorders, the treatment of most forms of arthritis is aimed at controlling joint inflammation and pain. In order to control the pain symptoms, patients with OA are usually treated with various oral analgesics. However, systemic long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) or opioids is limited in efficacy and by safety concerns. Thus, poorly controlled pain finally drives end-stage individuals to seek surgical therapy that specifically replaces the affected joints. Safer and more efficacious drug agents for managing arthritic disorders and arthritis-related pain are urgently needed. Early diagnosis is critical to the effective treatment of any form of the arthritic disorder. Joint inflammation (particularly synovitis) contributes significantly to pathogenesis and plays important role in the peripheral mechanisms of pain sensitization in osteoarthritis and rheumatoid arthritis. Destruction of cartilage is not reversible, and if the inflammation of arthritic disease isn't treated well, both cartilage and bone can be damaged. It is thought that joint inflammation emerges as a promising target for controlling arthritis. Considerable progress has been made in delineating the cellular and molecular mechanisms that underlie joint inflammation and pain in the development of arthritic disorders. Many drug candidates have been reported for arthritic treatment in lab research, although their efficacy needs more time to be validated in clinical use.
Under this Research Topic, we welcome the Original Research Articles, Methods, and Reviews that explore the effects and mechanisms in the occurrence and development of arthritic disorders and the development of innovative diagnostic and therapeutic strategies. The following directions are especially welcome:
(1) Identifying drug targets and their mediated regulatory mechanisms associated with arthritic disorders including their occurrence and development.
(2) The action mechanisms of potential drug regulation during arthritic disorders, including ankylosing spondylitis, gout, juvenile idiopathic arthritis, osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, septic arthritis, and thumb arthritis.
(3) Targeting new mechanisms and new targets to develop potential new agents against varieties of arthritic disorders.
Arthritis is the most common form of the joint disease affecting estimated millions of people worldwide, including ankylosing spondylitis, gout, juvenile idiopathic arthritis, osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, septic arthritis, thumb arthritis. The most common signs and symptoms of arthritis predominantly involve one or more joints, including joint pain, stiffness, swelling, redness, and functional limitation of affected joints. Despite the underlying etiologies varying in different types of arthritic disorders, the treatment of most forms of arthritis is aimed at controlling joint inflammation and pain. In order to control the pain symptoms, patients with OA are usually treated with various oral analgesics. However, systemic long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) or opioids is limited in efficacy and by safety concerns. Thus, poorly controlled pain finally drives end-stage individuals to seek surgical therapy that specifically replaces the affected joints. Safer and more efficacious drug agents for managing arthritic disorders and arthritis-related pain are urgently needed. Early diagnosis is critical to the effective treatment of any form of the arthritic disorder. Joint inflammation (particularly synovitis) contributes significantly to pathogenesis and plays important role in the peripheral mechanisms of pain sensitization in osteoarthritis and rheumatoid arthritis. Destruction of cartilage is not reversible, and if the inflammation of arthritic disease isn't treated well, both cartilage and bone can be damaged. It is thought that joint inflammation emerges as a promising target for controlling arthritis. Considerable progress has been made in delineating the cellular and molecular mechanisms that underlie joint inflammation and pain in the development of arthritic disorders. Many drug candidates have been reported for arthritic treatment in lab research, although their efficacy needs more time to be validated in clinical use.
Under this Research Topic, we welcome the Original Research Articles, Methods, and Reviews that explore the effects and mechanisms in the occurrence and development of arthritic disorders and the development of innovative diagnostic and therapeutic strategies. The following directions are especially welcome:
(1) Identifying drug targets and their mediated regulatory mechanisms associated with arthritic disorders including their occurrence and development.
(2) The action mechanisms of potential drug regulation during arthritic disorders, including ankylosing spondylitis, gout, juvenile idiopathic arthritis, osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, septic arthritis, and thumb arthritis.
(3) Targeting new mechanisms and new targets to develop potential new agents against varieties of arthritic disorders.